Review Article

Menopausal Hormone Treatment in Postmenopausal Women: Risks and Benefits

Authors: George V. Dous, MD, Richard Grodman, MD, Adenieki Mornan, MPH, Philip Otterbeck, MD, Angela Grigos, MD

Abstract

Our objectives in this review were to examine the relevant menopausal hormone treatment (MHT) trials in postmenopausal women during the past 3 decades, provide an insight analysis of these studies from a clinical point of view, determine the efficacy and applicability of hormone therapy in the prevention of cardiovascular diseases, and provide suggestions on the use of MHT as a cardiovascular disease prophylaxis based on the available data. MHT may have a more complicated role in cardiovascular protection, and there is a need for further research to elucidate the dose and type of estrogen, its route of administration, the time of MHT initiation, and the preventive role of MHT in women’s health.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

1. Mosca L, Banka CL, Benjamin EJ, et al. Evidence-based guidelines for cardiovascular disease prevention in women: 2007 update. J Am Coll Cardiol 2007;49:1230-1250.
 
2. Lloyd-Jones DM, Leip EP, Larson MG, et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006;113:791-798.
 
3. Mosca L, Linfante AH, Benjamin EJ, et al. National study of physician awareness and adherence to cardiovascular disease prevention guidelines. Circulation 2005;111:499-510.
 
4. Bush TL. Evidence for primary and secondary prevention of coronary artery disease in women taking oestrogen replacement therapy. Eur Heart J 1996;17(Suppl D):9-14.
 
5. Lindquist P, Bengtsson C, Lissner L, et al. Cholesterol and triglyceride concentration as risk factors for myocardial infarction and death in women, with special reference to influence of age. J Intern Med 2002;251:484-489.
 
6. Tikkanen MJ, Nikkila EA, Vartiainen E. Natural oestrogen as an effective treatment for type-II hyperlipoproteinaemia in postmenopausal women. Lancet 1978;2:490-491.
 
7. Granfone A, Campos H, McNamara JR, et al. Effects of estrogen replacement on plasma lipoproteins and apolipoproteins in postmenopausal, dyslipidemic women. Metabolism 1992;41:1193-1198.
 
8. Lobo RA. Clinical review 27: effects of hormonal replacement on lipids and lipoproteins in postmenopausal women. J Clin Endocrinol Metab 1991;73:925-930.
 
9. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991;325:1196-1204.
 
10. Soma MR, Osnago-Gadda I, Paoletti R, et al. The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapyin postmenopausal women. Arch Intern Med 1993;153:1462-1468.
 
11. Rosano GM, Vitale C, Fini M. Hormone replacement therapy and cardioprotection: what is good and what is bad for the cardiovascular system? Ann N Y Acad Sci 2006;1092:341-348.
 
12. Yeboah J, Reboussin DM, Waters D, et al. Effects of estrogen replacement with and without medroxyprogesterone acetate on brachial flow-mediated vasodilator responses in postmenopausal women with coronary artery disease. Am Heart J 2007;153:439-444.
 
13. Ahmed MA, Hassanein KM. Effects of estrogen on hyperglycemia and liver dysfunction in diabetic male rats. Int J Physiol Pathophysiol Pharmacol 2012;4:156-166.
 
14. Collins P, Rosano GM, Sarrel PM, et al. 17 Beta-estradiol attenuates acetylcholine-induced coronary arterial constriction in women but not men with coronary heart disease. Circulation 1995;92:24-30.
 
15. Zhou K, Gao Q, Zheng S, et al. 17A-Estradiol induces vasorelaxation by stimulating endothelial hydrogen sulfide release. Mol Hum Reprod 2013;19:169-176.
 
16. Hishikawa K, Nakaki T, Marumo T, et al. Up-regulation of nitric oxide synthase by estradiol in human aortic endothelial cells. FEBS Lett 1995;360:291-293.
 
17. Hayashi T, Yamada K, Esaki T, et al. Estrogen increases endothelial nitric oxide by a receptor-mediated system. Biochem Biophys Res Commun 1995;214:847-855.
 
18. Caulin-Glaser T, Garcia-Cardena G, Sarrel P, et al. 17 Beta-estradiol regulation of human endothelial cell basal nitric oxide release, independent of cytosolic Ca2+ mobilization. Circ Res 1997;81:885-892.
 
19. Castanho VS, Nakamura RT, Pinto-Neto AM, et al. Postmenopausal therapy reduces catalase activity and attenuates cardiovascular risk. Arq Bras Cardiol 2012;99:1008-1014.
 
20. White RE, Gerrity R, Barman SA, et al. Estrogen and oxidative stress: a novel mechanism that may increase the risk for cardiovascular disease in women. Steroids 2010;75:788-793.
 
21. Lee TM, Chou TF, Tsai CH. Differential role of K(ATP) channels activated by conjugated estrogens in the regulation of myocardial and coronary protective effects. Circulation 2003;107:49-54.
 
22. Brosnan JF, Sheppard BL, Norris LA. Haemostatic activation in post-menopausal women taking low-dose hormone therapy: less effect with transdermal administration? Thromb Haemost 2007;97:558-565.
 
23. Valera MC, Gratacap MP, Gourdy P, et al. Chronic estradiol treatment reduces platelet responses and protects mice from thromboembolism through the hematopoietic estrogen receptor . Blood 2012;120:1703-1712.
 
24. Sumino H, Ichikawa S, Kasama S, et al. Different effects of oral conjugated estrogen and transdermal estradiol on arterial stiffness and vascular inflammatory markers in postmenopausal women. Atherosclerosis 2006;189:436-442.
 
25. Campagnoli C, Belforte P, Di Sario MM, et al. Lipid profile during hormone replacement therapy: effect of different progestins? Zentralbl Gynakol 1997;119(Suppl 2):1-6.
 
26. Honisett SY, Pang B, Stojanovska L, et al. Progesterone does not influence vascular function in postmenopausal women. J Hypertens 2003;21:1145-1149.
 
27. Barbagallo M, Dominguez LJ, Licata G, et al. Vascular effects of progesterone: role of cellular calcium regulation. Hypertension 2001;37:142-147.
 
28. Lin AL, McGill HC, Shain SA. Hormone receptors of the baboon cardiovascular system. Biochemical characterization of aortic and myocardial cytoplasmic progesterone receptors. Circ Res 1982;50:610-616.
 
29. Hettiaratchi ES, Pickford M. The effect of oestrogen and progesterone on the pressor action of angiotensin in the rat. J Physiol 1968;196:447-451.
 
30. Nakamura H, Kurokawa J, Bai CX, et al. Progesterone regulates cardiac repolarization through a nongenomic pathway: an in vitro patch-clamp and computational modeling study. Circulation 2007;116:2913-2922.
 
31. Nakamura H, US Preventive Services Task Force. Menopausal hormone therapy for the primary prevention of chronic conditions: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2013;158:47-54.
 
32. Manson JE, Hsia J, Johnson KC, et al. Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 2003;349:523-534.
 
33. Rossouw JE, PrenticeRL, Manson JE, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA 2007;297:1465-1477.
 
34. Schierbeck LL, Rejnmark L, Tofteng CL, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ 2012;345:e6409.
 
35. Lacroix AZ, Chlebowski RT, Manson JE, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA 2011;305:1305-1314.
 
36. Khan MA, Heagerty AM, Kitchener H, et al. Oestrogen and women’s heart disease: ESPRIT-UK. QJM 2000;93:699-700.
 
37. Hodis HN, Mack WJ, Azen SP, et al. Hormone therapy and the progression of coronary-artery atherosclerosis in postmenopausal women. N Engl J Med 2003;349:535-545.
 
38. Wells G, Herrington DM. The Heart and Estrogen/Progestin Replacement Study: what have we learned and what questions remain? Drugs Aging 1999;15:419-422.
 
39. Harman SM, Brinton EA, Cedars M, et al. KEEPS: the Kronos Early Estrogen Prevention Study. Climacteric 2005;8:3-12.
 
40. Collins P, Flather M, Lees B, et al. Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. Eur Heart J 2006;27:2046-2053.
 
41. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA 1995;273:199-208.
 
42. Karim R, Mack WJ, Lobo RA, et al. Determinants of the effect of estrogen on the progression of subclinical atherosclerosis: Estrogen in the Prevention of Atherosclerosis Trial. Menopause 2005;12:366-373.
 
43. Hodis HN, Mack WJ, Lobo RA, et al. Estrogen in the prevention of atherosclerosis. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2001;135:939-953.
 
44. Waters DD, Alderman EL, Hsia J, et al. Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial. JAMA 2002;288:2432-2440.
 
45. Lakoski SG, Brosnihan B, Herrington DM. Hormone therapy, C-reactive protein, and progression of atherosclerosis: data from the Estrogen Replacement on Progression of Coronary Artery Atherosclerosis (ERA) trial. Am Heart J 2005;150:907-911.
 
46. Barrett-Connor E, Stuenkel CA. Hormone replacement therapy (HRT)—risks and benefits. Int J Epidemiol 2001;30:423-426.
 
47. Seibel MJ. Biochemical markers of bone turnover, part II: clinical applications in the management of osteoporosis. Clin Biochem Rev 2006;27:123-138.
 
48. Manson JE, Chlebowski RT, StefanickML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women’s Health Initiative randomized trials. JAMA 2013;310:1353-1368.